Life sciences company Merck KGaA (MRK: DE) revealed declining sales and profits in its latest quarterly sales figures, but the sums still exceeded the expectations of analysts.
Sales at the German firm decreased organically by 1.1% to 5.3 billion euros ($5.3 billion) in second-quarter 2023.
Earnings before interest, taxes, depreciation and amortization (EBITDA), before one-offs, dropped 7% to 1.6 billion euros.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze